基于基因的自然杀伤细胞疗法治疗儿科血液系统恶性肿瘤。
Gene-Based Natural Killer Cell Therapies for the Treatment of Pediatric Hematologic Malignancies.
机构信息
The Sidney Kimmel Comprehensive Cancer Center, Johns Hopkins University School of Medicine, 1650 Orleans Street, Baltimore, MD 21287, USA; Department of Pediatrics, Johns Hopkins University School of Medicine, Baltimore, MD, USA.
The Sidney Kimmel Comprehensive Cancer Center, Johns Hopkins University School of Medicine, 1650 Orleans Street, Baltimore, MD 21287, USA.
出版信息
Hematol Oncol Clin North Am. 2022 Aug;36(4):745-768. doi: 10.1016/j.hoc.2022.03.007. Epub 2022 Jun 27.
Pediatric blood cancers are among the most common malignancies that afflict children. Intensive chemotherapy is not curative in many cases, and novel therapies are urgently needed. NK cells hold promise for use as immunotherapeutic effectors due to their favorable safety profile, intrinsic cytotoxic properties, and potential for genetic modification that can enhance specificity and killing potential. NK cells can be engineered to express CARs targeting tumor-specific antigens, to downregulate inhibitory and regulatory signals, to secrete cytokine, and to optimize interaction with small molecule engagers. Understanding NK cell biology is key to designing immunotherapy for clinical translation.
儿科血液癌是儿童最常见的恶性肿瘤之一。在许多情况下，强化化疗并不能治愈，因此迫切需要新的治疗方法。由于 NK 细胞具有良好的安全性、内在的细胞毒性特性以及可增强特异性和杀伤潜力的遗传修饰潜力，因此它们有望作为免疫治疗效应物使用。可以对 NK 细胞进行工程改造，使其表达针对肿瘤特异性抗原的 CAR，下调抑制和调节信号，分泌细胞因子，并优化与小分子配体的相互作用。了解 NK 细胞生物学是将免疫疗法应用于临床转化的关键。
Zotero 插件